Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 5/20 | 0.61 |
| ▸ | CMA1 | P23946 | 2/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | TDP2 | O95551 | 8/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.38 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.37 |
| ▸ | CACNG8 | Q8WXS5 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | CASP9 | P55211 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL223361 | 0.81 | AHR (0.58) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL31116942 | 0.81 | AHR (0.53) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL18554774 | 0.81 | AHR (0.53) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL18289475 | 0.80 | AHR (0.59) | AHRCMA1TDP2PDK2EIF2AK2 | |
| SCHEMBL25424110 | 0.77 | CES1 (0.55) | AHRCMA1CES1TDP2 | |
| SCHEMBL30415778 | 0.77 | CES1 (0.55) | AHRCMA1CES1TDP2 | |
| SCHEMBL1162926 | 0.76 | AHR (1.00) | AHRCMA1CES1TDP2PDK2 | |
| SCHEMBL9837197 | 0.72 | AHR (0.57) | AHRCMA1CES1 | |
| SCHEMBL31057841 | 0.71 | AHR (0.43) | AHRCMA1TDP2PDK2GRM5 | |
| SCHEMBL3284838 | 0.71 | AHR (0.86) | AHRCES1TDP2PDK2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | CONNEXIOS LIFE SCIENCES PVT. LIMITED (IN) | 2016-05-12 | — | — | US | disclosed |
| EP-3010905-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | Boehringer Ingelheim International GmbH (DE) | 2016-04-27 | — | — | EP | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014202580-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130226-A1 | SPIRO-SUBSTITUTED OXINDOLE DERIVATIVES HAVING AMPK ACTIVITY | AK2, PRKAA2, PRKAA1 | AHR 1232/4885CMA1 4653/4885CES1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.